Timing of recurrent uveitis in patients with Behçet's disease receiving infliximab treatment

British Journal of Ophthalmology

Volumn 95, Issue 2, 2011, Pages 205-208

  Yamada, Yukiko ^a   Sugita, Sunao ^a   Tanaka, Hiroyuki ^a   Kamoi, Koju ^a   Takase, Hiroshi ^a   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOSPORIN A; INFLIXIMAB; PREDNISOLONE;

ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG WITHDRAWAL; HUMAN; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UVEORETINITIS;

ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; UVEITIS;

EID: 79251468764     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.168856     Document Type: Article

References (29)

1. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum 1998;27:197-217.
2. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. N Engl J Med 1999;341:1284-91.
3. International Study Group for Behçet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-80.
4. Ohno S, Ohguchi M, Hirose S, et al. Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol 1982;100:1455-8.
5. Verity DH, Marr JE, Ohno S, et al. Behçet's disease, the silk road and HLA-B51: historical and geographical perspectives. Tissue Antigens 1999;54:213-20.
6. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet's disease. Ann Rheum Dis 2008;67:1656-62.
7. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease - an update. Semin Arthritis Rheum 2001;30:299-312.
8. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet's disease. Am J Ophthalmol 2008;146:845-50.
9. Lim L, Suhler EB, Smith JR. Biologic therapies for inflammatory eye disease. Clin Exp Ophthalmol 2006;34:365-74. (Pubitemid 44137557)
10. Kotter I, Gunaydin I, Zierhut M, et al. The use of interferon α in Behcet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-35.
11. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonist - preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007;27:399-413.
12. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
13. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999;354:1932-9.
14. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359:1541-9.
15. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004;31:1362-8.
16. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001;358:295-6.
17. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 2001;358:1644.
18. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in adamantiades-Behçet's disease. Ann Intern Med 2004;140:404-6.
19. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. An open label trial. Arthritis Rheum 2005;52:2478-84.
20. Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 2007;51:191-6. (Pubitemid 46889493)
21. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology 2007;46:1161-4.
22. Al-Rayes H, Al-Swailem R, Al-Balawi M, et al. Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label trial. Rheumatol Int 2008;29:53-7.
23. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus cyclosporine in the initial 6 months of the treatments in Behçet's disease. Br J Ophthalmol 2010;94:284-8.
24. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 2007;46:736-41.
25. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
26. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009;65:1121-8.
27. Krzysiek R, Breban M, Ravaud P, et al. Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 2009;61:569-76.
28. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210-26.
29. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009;15:1264-75.